AdAlta appoints Melbourne-based Cell Therapies as preferred manufacturing partner

Latest News

AdAlta (ASX:1AD)  has announced an agreement under which Cell Therapies will be established as the preferred manufacturing partner of its cellular immunotherapies.

Cell Therapies is a contract development and manufacturing organisation based in the Melbourne Biomedical Precinct.

Cell Therapies (CTPL) will support AdCella, AdAlta’s cellular immunotherapy collaboration with SYNthesis BioVentures (SYNBV), with key product development, manufacturing and supply chain capabilities.

CTPL CEO Dr Bev Menner said, "We are very pleased to partner with AdAlta and AdCella to bring the cellular immunotherapy innovation we see in Asia to Australian and global patients in need. We are impressed by the vision and expertise of AdAlta and SYNBV and we are confident that our experience and networks enable us to provide them with high-quality product development, manufacturing and clinical supply services that meet the expectations of regulators around the world."

AdAlta CEO and Managing Director Dr Tim Oldham said, "This collaboration with CTPL is the next key building block in our strategy to bring highly innovative cellular immunotherapies into a western regulated environment. CTPL’s demonstrated expertise over many years and multiple clients ensures that we will have access to the skills, experience and facilities needed to realise this goal, and importantly that we can immediately demonstrate this to our in-licensing partners."